Candidemia in critically ill immunocompromised patients: report of a retrospective multicenter cohort study.

ABSTRACT:

Background

Immunocompromised critically ill patients constitute a population with the high risk of candidemia. This retrospective study aimed to assess the outcome of immunocompromised critically ill patients with candidemia. Secondary objectives were to describe clinical phenotypes of these patients, Candida ecology, and factors associated with mortality.

Results

Overall, 121 patients were included in this study. Median delay from candidemia to first antifungal therapy was 3 days, in line with the observed delay of blood culture positivity. Candia albicans was the main Candida specie identified (54%), and susceptibility of Candida to fluconazole and echinocandins was of, respectively, 70% and 92%. Hospital mortality was of 60%. After adjustment for confounders, severity as

SUBMITTER: Ghrenassia E 

PROVIDER: S-EPMC6546779 | biostudies-literature | 2019 Jun

REPOSITORIES: biostudies-literature